DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome

Information source: National Taiwan University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Marfan Syndrome

Intervention: Losartan and Atenolol or Propranolol (Drug); Atenolol or Propranolol (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: National Taiwan University Hospital

Official(s) and/or principal investigator(s):
Mei-Hwan Wu, Principal Investigator, Affiliation: National Taiwan University Hospital

Overall contact:
Hsin-Hui Chiou, Phone: 886-2-2312-3456, Ext: 3160, Email: eliachiou@yahoo.com.tw


To assess the efficacy of angiotensin II receptor blocker, Losartan, to prevent progressive dilation of aortic root in patients with Marfan syndrome.

Clinical Details

Official title: A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: Echocardiograms

Detailed description: Marfan syndrome (MFS) is a multisystem connective tissue disorder of autosomal dominant inheritance1. The cardinal features are noted in the cardiovascular, ocular, and skeletal system. The most life-threatening complication of MFS is progressive aortic root dilation leading to aortic dissection or rupture. Losartan, an angiotensin II type I receptor (AT1) antagonist, is a drug already in clinical use for hypertension and type II diabetic nephropathy. A recent study showed that Losartan prevents aortic root dilation and lung problem in a mouse model of MFS. Therefore, the goals of this clinical trial are to examine the efficacy and safety of Losartan in patients with Marfan syndrome for aortic root dilation prevention.


Minimum age: 1 Year. Maximum age: N/A. Gender(s): Both.


Inclusion criteria

- Marfan syndrome with recognized aortic root dilation

- Patients must be older than one year of age

- Beta-blocker treatment at least three months

- Must sign an informed consent form

Exclusion criteria

- Prior to aortic root surgery

- Aortic root dimension more than 5. 5cm

- Aortic surgery within 6 months

- Diabetes mellitus or liver and renal dysfunction or asthma

- Pregnancy

- Intolerance to Losartan therapy

Locations and Contacts

Hsin-Hui Chiou, Phone: 886-2-2312-3456, Ext: 3160, Email: eliachiou@yahoo.com.tw

National Taiwan University Hospital, Taipei 100, Taiwan; Recruiting
Additional Information

Starting date: February 2007
Last updated: June 8, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017